Search

Your search keyword '"Tavolaro, Simona"' showing total 153 results

Search Constraints

Start Over You searched for: Author "Tavolaro, Simona" Remove constraint Author: "Tavolaro, Simona"
153 results on '"Tavolaro, Simona"'

Search Results

5. Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

7. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

10. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia

12. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes

16. Genetic Landscape and Gene Expression Profile of Chronic Lymphocytic Leukemia Patients with Ultra-Stable Disease

17. Genetic Landscape and Gene Expression Profile of Chronic Lymphocytic Leukemia Patients with Ultra-Stable Disease

18. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations

20. Evaluation of gene expression profiling in Chronic Lymphocytic Leukemia

21. Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR‐132 and miR‐212

22. BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion

23. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

24. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

25. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis

26. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes

28. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling

30. ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression.

31. Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML)

32. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

33. IgVH Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.

34. Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.

35. Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors.

36. The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgVH Mutated and Unmutated Patients.

37. Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.

38. Angiogenic Activity in IgVH Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.

40. Detection of the NUP214-ABL Rearrangement in T-ALL by High-Density Oligonucleotide Arrays: Evidence of the Value of This Approach in the Identification of Gene Amplifications.

41. Effective Targeting of MEK/ERK Signalling at Nanomolar Concentrations by the Novel Small Molecule Inhibitor PD0325901 in Hematopoietic and Solid Tumors.

43. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVHunmutated chronic lymphocytic leukemia (CLL) cells

44. The microRNA (miR) profile in B-cell chronic lymphocytic leukemia (CLL) reveals a differential expression of miR-21, miR-155 and miR-150 between leukemic and normal B lymphocytes, and of miR-150, miR-29bc and miR-223 between IgV(H) mutated and unmutated patients

45. BIRC3disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion

46. IgVHGermline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.

47. Angiogenic Activity in IgVHMutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.

48. The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgVHMutated and Unmutated Patients.

49. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis

50. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Catalog

Books, media, physical & digital resources